Lv11
30 积分 2024-01-21 加入
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
5小时前
待确认
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China
18天前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
20天前
已完结
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
20天前
已完结
OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma
21天前
已完结
Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis
22天前
已完结
Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT
22天前
已完结
AntiCD30-Conjugated Antibody Plus Standard BEAM as Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Systemic Anaplastic Large Cell Lymphoma
23天前
已完结
Refractory DLBCL: Challenges and Treatment
26天前
已完结
[Guidelines for the diagnosis and management of multiple myeloma: 2024 updates]
28天前
已完结
皖公网安备34019202002308
